Health Care [ 11/12 ] | Biotechnology [ 53/76 ]
NASDAQ | Common Stock
Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases.
The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.
It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease.
The company was incorporated in 2017 and is based in New York, New York.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 28, 24 | 0.00 | -0.69 Increased by +100.00% |
| Nov 6, 23 | -12.36 | -2.60 Decreased by -375.38% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 0.00 Decreased by -100.00% | -20.11 M Decreased by -32.79% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 - | -13.44 M - | Decreased by N/A% - |
| Dec 31, 22 | 0.00 - | -14.58 M - | Decreased by N/A% - |
| Sep 30, 22 | 531.00 K - | -17.05 M - | Decreased by -3.21 K% - |
| Jun 30, 22 | 37.00 K - | -15.14 M - | Decreased by -40.93 K% - |